Metis Global Partners LLC Has $253,000 Holdings in DaVita Inc. (NYSE:DVA)

Metis Global Partners LLC decreased its position in shares of DaVita Inc. (NYSE:DVA) by 7.0% in the third quarter, Holdings Channel reports. The fund owned 1,543 shares of the company’s stock after selling 117 shares during the period. Metis Global Partners LLC’s holdings in DaVita were worth $253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Harvard Management Co. Inc. acquired a new position in shares of DaVita during the 2nd quarter worth about $55,115,000. Lazard Asset Management LLC lifted its holdings in shares of DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after buying an additional 153,008 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of DaVita in the second quarter worth $9,615,000. KBC Group NV increased its position in DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after acquiring an additional 67,250 shares during the period. Finally, International Assets Investment Management LLC acquired a new position in DaVita during the 3rd quarter valued at $10,346,000. 90.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. This represents a 36.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock worth $24,807,161 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $156.98 on Wednesday. The business has a 50 day simple moving average of $157.99 and a 200 day simple moving average of $147.88. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market capitalization of $12.87 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 0.90 and a beta of 0.89. DaVita Inc. has a one year low of $95.60 and a one year high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.85 earnings per share. On average, sell-side analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DVA shares. Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.